CEO Mark Diamond on SC webinar @ 12:30pm TODAY, page-38

CompaniesFACEBOOKTWITTERLINKEDINBy ANDREW BEATTIE Updated September 02, 2021Reviewed by THOMAS BROCKThere are many reasons to feel uncomfortable investingt in drug companies. For many investors targeting the next big pharmaceutical breakthrough, the biggest obstacle is knowing how to evaluate drug companies as investments. Another concern is whether these companies will be successful in winning approval from the Food and Drug Administration (FDA) and bringing their products to market.——————-
Considering Startup Pharma Opportunities Established companies are almost always safer as investments than new ones. If there is an up-and-coming company with an unbeatable drug, a major firm will usually come I along and partner with the smaller firm, or buy it outright. This is a safe move for the startup as well because in it will gain access to the larger company's distribution channels. Additionally, if the FDA puts the brakes on a drug's development, a larger firm has the capital to take it back to the lab again.————-
/However, small firms with a history of partnering to get drugs out of the lab and into the world are worth considering. When it comes to acquisitions, large companies typically look for smaller firms valued at $1 billion to $5 billion, with drug candidates in the mid- to late-stage clinical trials. These are called "bolt-on" transactions, and they help large companies to fill out their pipeline.Some startups choose to go solo and market drugs directly to doctors in cities where the illness is most prevalent.————-
These startups are often wildly successful in this endeavor, but these are exceptions. Most investors are hesitant to back new biotech companies, and in their fledgling stage they are usually considered a gamble !!———-
The Importance of Pending Drug Developments The strength of the drug pipeline is vital to pharmaceutical companies of all sizes. This is the primary measure of whether a company is a good investment. The term for a new drug patent is 20 years before generic producers can enter the market and lower the price.3 As a result, companies, especially startups, are on shaky ground if they depend on just one drug for all their profits.—————-
To counter this uncertainty, companies try to keep their pipelines flowing. Developing drugs in the pharmaceutical industry is a bit like throwing darts in the dark. The more darts you throw, the better your chances are of hitting the mark. You can check how many drugs a company has in the pipeline within the company's financial statementGet Outlook for iOSSo what have we concluded from the Above ?1) it takes 20 yrs to develop a drug .. cost $2 billion2)Anp will Partner some of our pipeline in due course 3)Anp will be in the range $1 billion to $5 billion to. Partner4)Some start ups decide to go solo like Anp and have decided to market their drugs directly to Doctors5)Anp will have a very strong pipeline once all is revealed... 6) In a previous article it said it takes 20 yrs to develop a . Drug at a cost $2 billion.
Anp done it in 13 at a cost less than $500 mill7)So for all you People who winge and have nothing . better to do than be negative and rude to Diamond and the Board…. Think again. … you are not experts ..and have nothing concrete to contribute excepta) Diamonds presentation….( he concentrates on Science and Data and does wear a Gucci suit)b)Sp going down c)Nothing happening for a couple of months..Conclusion If one is patient and looks at the Sp in 3 yrs it will be over $5 ++But don’t despair .. you can sell at any time below $5….We are all shareholders trying to make a few dollars… play the game “Patience”